GNBT - Generex Biotechnology Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
1.8600
+0.0700 (+3.91%)
At close: 3:50PM EDT
Stock chart is not supported by your current browser
Previous Close1.7900
Open1.8350
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.7700 - 1.9500
52 Week Range0.0838 - 3.1000
Volume91,520
Avg. Volume53,909
Market Cap112.274M
Beta (3Y Monthly)-4.60
PE Ratio (TTM)3.68
EPS (TTM)0.5060
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    Generex Provides Update to Pending 1:1 Stock Dividend

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), in response to the large volume of investor calls, today provided an update on its new 1:1 dividend that has been approved by the Generex Board of Directors and as previously announced, will be declared on June 20, 2019, subject to any necessary regulatory approvals. This dividend will be tied to a NASDAQ or NYSE stock listing and will be paid on the day the Company is up-listed.

  • GlobeNewswire12 days ago

    Generex Biotechnology CEO Joe Moscato To Present at H.C. Wainwright Healthcare Conference

    Generex Biotechnology Corporation (GNBT) is pleased to announce that Joe Moscato, the company’s Chief Executive Officer and his team of seasoned industry leaders are scheduled to present at the H.C. Wainwright Global Investor Conference to be held in New York from September 8 to 10. Mr. Moscato will present the Generex corporate strategy and operating results and will be meeting with leading healthcare investors to present the corporate vision for Generex Biotechnology as an integrated healthcare holding company with a unique strategy to provide end-to-end, patient centric solutions to enhance the doctor patient relationship. “We are proud and honored to be asked to present the “New” Generex at the H.C. Wainwright conference,” stated Joe Moscato, CEO of Generex.

  • GlobeNewswire13 days ago

    Generex Biotechnology Announces Date for Rescheduled May 15th Investor Conference Call to Present Organizational Roadmap & Update on Investor Dividend, Product Launch, New Acquisitions, Financing, Expansion Initiatives & Strategic Plans

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has rescheduled the investor conference call originally scheduled for May 15, 2019. The new date for the call will be June 21, 2019, at which time Joseph Moscato, President & Chief Executive Officer of Generex will present an organizational roadmap outlining Generex Biotechnology’s operational, strategic and financial plans, as outlined herein.

  • GlobeNewswire16 days ago

    Generex Biotechnology Announces Share Dividend & Strategic Plans

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company plans to declare a 1:1 stock dividend, contingent upon the successful up listing to NASDAQ, to complete the strategic reorganization from a pure development company to a an end-to-end solutions provider for physicians and patients. Joseph Moscato, CEO of Generex stated, “On June 20th, Generex plans to declare a 1 for 1 dividend for shareholders of record with certain conditions, noting that verbal commitments have been given that the dividend will be waived by all insiders and other major equity holders not in the public float. Once that is formalized, this dividend will be the last dividend from the company in conjunction with its completion of its current overall three-stage development plan.

  • GlobeNewswirelast month

    Generex Biotechnology Announces that its Subsidiary Olaregen Therapeutix Launches Excellagen at The Symposium on Advanced Wound Care (SAWC) in San Antonio, TX

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that its Subsidiary, Olaregen Therapeutix has officially launched Excellagen Wound Conforming Matrix. Generex and Olaregen launched Excellagen during its debut at The Symposium on Advanced Wound Care (SAWC) in San Antonio, TX. SAWC is the premier interdisciplinary wound care program in the United States.

  • GlobeNewswirelast month

    Generex Biotechnology Announces Postponement of Its May 15th Investor Conference Call

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has postponed the investor conference call scheduled for May 15, 2019.  Joseph Moscato, President & Chief Executive Officer of Generex expressed the need to reschedule the call as the company finalizes two current deals.  “We feel it is best to finalize these initiatives so that we can present our plan to our investors and shareholders in its entirety,” stated Joseph Moscato.  “We have made a point to conduct investor conference call every month to two, so I am disappointed by this postponement. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies.

  • GlobeNewswirelast month

    Generex Biotechnology Subsidiary NuGenerex Diagnostics Announces Sales for its Rapid Point-of-Care Malaria Diagnostic Test Kit

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that their wholly-owned subsidiary NuGenerex Diagnostics LLC, (www.nugenerexdiangostics.com) has filled an international order for 40,000 units of its malarial diagnostic product, The NGDx -Malaria PF/PV Cassette Test Kit to Imres, BV, a Netherlands-based medical distribution company. NuGenerex Diagnostics is fully qualified as a diagnostic test developer and manufacturer under FDA Good Manufacturing Procedures (GMP) and is certified by the International Standards Organization for the manufacture of medical devices under ISO 13485-2016 regulations.

  • PR Newswire2 months ago

    Generex Biotechnology Announces Organizational Roadmap & Investor Conference Call: Update on Product Launch, New Acquisitions, Financing, Expansion Initiatives & Strategic Plans

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has scheduled an investor conference call for May 15, 2019 with Joseph Moscato, President & Chief Executive Officer of Generex who will present an organizational roadmap outlining Generex Biotechnology's operational, strategic and financial plans, as outlined herein.

  • GlobeNewswire2 months ago

    Generex Biotechnology Subsidiary Olaregen Therapeutix Sponsors Prestigious Diabetic Limb Salvage Conference in Washington D.C.

    MIRAMAR, FL, April 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company’s subsidiary Olaregen Therapeutix participated as a sponsor of the prestigious Diabetic Limb Salvage Conference in Washington, DC as part of its continued commitment to Wound Care Education. The Conference was attended by 600 influential experts and healthcare providers involved in the research and management of wounds, with specific emphasis on diabetic foot ulcers (DFUs). Lois Chandler, PhD, the inventor of Excellagen®, presented Wound Conforming Matrix (WCM) Promotes Rapid Healing of Diabetic Neuropathic Foot Ulcers: Subset Analysis of Randomized Controlled Trial at the Conference’s formal poster presentations.

  • GlobeNewswire2 months ago

    Kali-Extracts To Present Cannabis Treatment R&D For $170 Million In Pharmaceutical Market Opportunity On April 17th

    DALLAS, April 09, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an online presentation scheduled.

  • GlobeNewswire2 months ago

    Generex Biotechnology Corporation Appoints Mark J. Prioletti to the Board of Directors

    MIRAMAR, FL, April 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointment of Mark J. Prioletti to the Board of Directors. Mr. Prioletti had a distinguished career at Motorola, leading Channel Marketing & Sales, New Program Development, Partnership and Alliance Development to vastly expand the Motorola sales operations, which continually generated profitable revenue and growth for both emerging markets and mature businesses.

  • GlobeNewswire2 months ago

    Generex Addresses Shareholder Concern Over 8-K and Quarterly Filing

    MIRAMAR, FL, April 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex would like to clarify the discussions surrounding the filed 10-Q ending the period of January 31, 2019, or the second quarter, filed on March 25, 2019, and its subsequent non-reliance 8-K filed on March 28, 2019. Generex learned of this after the 10-Q was filed, and soon thereafter filed a non-reliance 8-K to safeguard its shareholders. Generex has been diligently working with its auditor to overcome accounting problems to rectify the situation as soon as possible, and expects the 10-Q/A to be filed shortly.

  • GlobeNewswire3 months ago

    Upmarket Deal at $2.50 Per Share Saves Generex Biotechnology Shareholders $14+ Million

    MIRAMAR, FL, March 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce that the company has successfully renegotiated a mutually agreed upon purchase price for certain assets of Veneto Holdings. As previously reported, on October 3, 2018, Generex affiliate NuGenerex Distribution Solutions 2, LLC (“NuGenerex”) agreed to purchase Veneto Group’s eight pharmacies, a wholesale pharmacy purchasing company, and an in-network laboratory.  In consideration, NuGenerex executed and delivered to Veneto a promissory note in the principal amount of US $15 Million (the “First Tranche Note”).

  • GlobeNewswire3 months ago

    Generex Biotechnology Partner Olaregen Therapeutix, Inc. Selected to Present a Formal Poster Session at Prestigious Diabetic Limb Salvage Meeting

    Excellagen Clinical Trial Analysis: Rapid Healing of Diabetic Neuropathic Foot Ulcers Presentation on Friday Evening April 5, 2019 at the JW Marriott Hotel in Washington,.

  • GlobeNewswire3 months ago

    USMJ and PURA Update Dividend Distribution Plans With PJET and NOUV To Include New Developments With WCVC and KALY

    DALLAS, March 22, 2019 -- via OTC PR WIRE -- North American Cannabis Holdings, Inc. (USOTC: USMJ) (“USMJ”) and Puration Inc. (USOTC: PURA) (“PURA”) today published an update on.

  • GlobeNewswire3 months ago

    KALY Phase One Cannabis Extract COPD Research To Be Published This Friday, March 22, 2019

    DALLAS, March 20, 2019 -- via OTC PR WIRE --   Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced the company plans to publish its.

  • GlobeNewswire3 months ago

    KALY Initiates Phase Two Cannabis Extract COPD Treatment Study

    DALLAS, March 18, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced Professor Jeffry Osbourn, Ph.D.,.

  • GlobeNewswire3 months ago

    Generex Biotechnology Announces the Appointment of Chief Commercial Officer

    MIRAMAR, FL, March 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), is proud to announce the appointment of Lance Goudzwaard as the Chief Commercial Officer for NuGenerex Distribution Solutions (NDS), the company’s wholly-owned subsidiary. Mr. Goudzwaard will be responsible for the delivery and operation of the management services organization (MSO) platform that is currently operational in five states, with an aggressive growth strategy designed to expand the model to 27 states in the next several months. Mr. Goudzwaard will also focus on building and developing our durable medical equipment (DME) service offering called DME-IQÔ, a software system being introduced to the orthopedic market with turnkey services to support the development and management of compliant and profitable in-office DME programs.

  • GlobeNewswire3 months ago

    KALY Cannabis Patent Featured In PURA Report On Progress Toward $5 Million Sales Goal

    DALLAS, March 08, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today announced the company’s recent advances developing a CBD extract for infusion into a beverage at a 25 mg concentration were featured in a report published yesterday by Puration, Inc. (PURA) (“PURA”).  PURA yesterday reported recent progress toward the company’s $5 million 2019 sales goal.  The report included an overview of KALY’s role using its patented extraction process to develop a CBD extract that will sustain suspension in a beverage at a consistent concentrate level of 25 mg.  The first target beverage for the 25 mg CBD concentrate beverage is a private labeled health water for Generex Biotechnology (GNBT).

  • GlobeNewswire3 months ago

    Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Appointment of Vice President of Business Strategy

    Industry Veteran John P. Sentman to Lead Strategic Sales and Partnering MIRAMAR, FL, March 08, 2019 -- via NEWMEDIAWIRE -- Olaregen Therapeutix, a subsidiary of Generex.

  • Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest
    GlobeNewswire3 months ago

    Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest

    DALLAS, March 07, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Puration, Inc. (PURA) today published a presentation, to review new orders, opportunities and partnerships stemming from the EVERx CBD Sports Water event this past weekend at the Arnold Sports Festival.

  • GlobeNewswire4 months ago

    Generex Investor Conference Call Now Available Online

    MIRAMAR, FL, March 01, 2019 -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced.

  • GlobeNewswire4 months ago

    PURA - Puration Announces Analyst Update Report Coming Thursday February 28, 2019

    DALLAS, Feb. 26, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  Puration, Inc. (PURA) today announced an upcoming analyst update report expected to be published this Thursday, February 28, 2019.  The report expected on Thursday will be a second update from Goldman Small Cap Research which initiated analyst coverage in October last year and published a first update in November of last year confirming a Speculative Buy and $0.25 Target PPS.  The company has since the first update signed additional contracts and launched an all new formulation and packaging of its EVERx CBD Sports Water.  Earlier today, the company previewed a major coming announcement regarding its EVERx CBD Sports Water planned for release later this week. The previewed announcement expected later this week is separate from the Analyst Report update planned for release on Thursday this week.  The update report is anticipated to include an assessment of PURA’s $1.5 million contract with Generex Biotechnology (GNBT) to produce custom, private ladled, CBD Infused water for Generex.  PURA is working with Kali-Extracts (KALY) to develop the customer CBD extract formulation for infusion into the water produced for Generex.

  • GlobeNewswire4 months ago

    Reminder: Investor Conference Call Today, February 26, 2019; Management to Provide Update on Initiatives & Strategic Plans, Call-in Details

    MIRAMAR, FL, Feb. 26, 2019 -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced.

  • GlobeNewswire4 months ago

    KALY – Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study

    DALLAS, Feb. 21, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today published a second preview of a pending full report on their long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process.  The first preview was published on February 5, 2019.  The full report is expected within the next 2 weeks. The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients.  The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.